Creative Medical Technology Holdings, Inc. (CELZ)
(Delayed Data from NSDQ)
$3.26 USD
-0.08 (-2.40%)
Updated Aug 2, 2024 03:12 PM ET
After-Market: $3.34 +0.08 (2.45%) 7:26 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Creative Medical Technology Holdings, Inc. [CELZ]
Reports for Purchase
Showing records 1 - 20 ( 44 total )
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Proprietary iPSC Derived Islet Cells Produce Human Insulin
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Files 10-Q, T1D Prevention Trial Cleared To Start, CLBP Trial Starts 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Files 10-K, T1D Prevention Trial Cleared To Start, CLBP Trial Starts 2Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
3Q23: Clinical Progress Across The Board, Funded Through YE24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Receives IRB Approval For AlloStem Phase 1/2 Trial In CLBP
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
FDA Clears Start of Phase 1/2 StemSpine Trial In Chronic Lower Back Pain
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
1 For 10 Reverse Split Moves PT To $30, $2M Share Buyback Announced
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Success with First Phase of Next Generation iPSC Pipeline Development
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Announces Advancements in Its Cell- Free ImmCelz Platform
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Positive Chronic Lower Back Pain Data Achieved With StemSpine AlloStem
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Reports Positive Top-Line One-Year Clinical Results In T1D Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J